Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Karlsson, P. Articles by Sedvall, G. Search for Related Content PubMed Citation Articles by Karlsson, P. Articles by Sedvall, G. Neurotransmitters Schizophrenia Spectrum Disorders PET

PET Study of D₁ Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia

OBJECTIVE: Postmortem studies and a positron emission tomography (PET) study have suggested that there is a disturbance of central D₁ dopamine receptor function in schizophrenia. The objective of the present PET study was to compare D₁ receptor binding in first-admission, neuroleptic-naive patients with schizophrenia and in healthy subjects. METHOD: Ten healthy comparison subjects and 10 neuroleptic-naive patients with schizophrenia (diagnosed according to DSM-III-R) were examined twice by PET using ¹¹C-labeled SCH 23390 ([¹¹C]SCH 23390) with high and low specific radioactivity, respectively. The binding potential, receptor density (B_max), and affinity (K_d) were determined for the caudate nucleus, the putamen, and several neocortical regions during both PET examinations. Scatchard plots from the two measurements were used to calculate regional D₁ B_max and K_d. The regional binding values were tested for hemispheric asymmetry and for correlation to clinical symptoms measured by the Brief Psychiatric Rating Scale (BPRS). RESULTS: [¹¹C]SCH 23390 binding to D₁ receptors did not differ significantly between subjects with schizophrenia and healthy subjects in any of the brain regions or for any of the binding measures studied. Asymmetry of the regional binding values did not differ significantly between the two groups. Scores on the BPRS negative symptom subscale correlated significantly with the B_max in the right frontal cortex. CONCLUSIONS: These results do not replicate previous postmortem and PET findings of altered central dopamine D₁ receptor binding in schizophrenia. The finding of a positive correlation between frontal D₁ binding and scores on the negative symptom subscale of the BPRS is contrary to a previously reported finding of a negative correlation. These discrepancies motivate further studies using D₁ ligands with higher signals for cortical regions.

This article has been cited by other articles:

				O. D. Howes and S. Kapur The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway Schizophr Bull, May 1, 2009; 35(3): 549 - 562. [Abstract] [Full Text] [PDF]

				O. D. HOWES, A. J. MONTGOMERY, M. ASSELIN, R. M. MURRAY, P. M. GRASBY, and P. K. McGUIRE Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis The British Journal of Psychiatry, December 1, 2007; 191(51): s13 - s18. [Abstract] [Full Text] [PDF]

				J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry, November 1, 2006; 63(11): 1189 - 1197. [Abstract] [Full Text] [PDF]

				J. Hirvonen, T. G.M. van Erp, J. Huttunen, S. Aalto, K. Nagren, M. Huttunen, J. Lonnqvist, J. Kaprio, T. D. Cannon, and J. Hietala Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia Am J Psychiatry, October 1, 2006; 163(10): 1747 - 1753. [Abstract] [Full Text] [PDF]

				A. Bertolino, G. Caforio, G. Blasi, M. De Candia, V. Latorre, V. Petruzzella, M. Altamura, G. Nappi, S. Papa, J. H. Callicott, et al. Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia Am J Psychiatry, October 1, 2004; 161(10): 1798 - 1805. [Abstract] [Full Text] [PDF]

				J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics Am J Psychiatry, September 1, 2004; 161(9): 1620 - 1625. [Abstract] [Full Text] [PDF]

				S. McGowan, A. D. Lawrence, T. Sales, D. Quested, and P. Grasby Presynaptic Dopaminergic Dysfunction in Schizophrenia: A Positron Emission Tomographic [18F]Fluorodopa Study Arch Gen Psychiatry, February 1, 2004; 61(2): 134 - 142. [Abstract] [Full Text] [PDF]

				A. Abi-Dargham and H. Moore Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia Neuroscientist, October 1, 2003; 9(5): 404 - 416. [Abstract] [PDF]

				P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319. [Abstract] [Full Text] [PDF]

				P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us